{
    "id": 1889,
    "fullName": "PGR positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PGR positive indicates the presence of the PGR gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5241,
        "geneSymbol": "PGR",
        "terms": [
            "PGR",
            "NR3C3",
            "PR"
        ]
    },
    "variant": "positive",
    "createDate": "09/25/2014",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16714,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Chidamide (CS055) in combination with Aromasin (exemestane) resulted in improved progression-free survival (7.4 vs 3.7 months, HR=0.755, p=0.0336), objective response rate (18.4% vs 9.1%), and clinical benefit rate (46.7% vs 35.5%) compared to placebo in patients with hormone receptor positive, ERBB2 (HER2)-negative breast cancer patients (ESMO 2018 Congress, Oct 2018, Presidential Symposium 1; NCT02482753).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 8155,
                "therapyName": "Chidamide + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14746,
                    "pubMedId": null,
                    "title": "Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer",
                    "url": "https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Phase-III-trial-of-chidamide-a-subtype-selective-histone-deacetylase-HDAC-inhibitor-in-combination-with-exemestane-in-patients-with-ho"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14540,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-7) that supported FDA approval, Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (Femara (letrozole) or Arimidex (anastrozole)) resulted in significantly improved median progression-free survival (23.8 vs 13.0 months, HR=0.55, p<0.0001) compared to placebo in premenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 29804902; NCT02278120).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11737,
                    "pubMedId": 29804902,
                    "title": "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29804902"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12604,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-2) that supported FDA approval, Kisqari (ribociclib) plus Femara (letrozole) as first-line therapy resulted in an 18 month progression-free survival rate of 63.0% compared to 42.2% with placebo plus Femara (letrozole), and an overall response rate of 52.7%, compared to 31.7% with placebo in patients with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 27717303; NCT01958021).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6802,
                    "pubMedId": 27717303,
                    "title": "Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27717303"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3028,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the recommended phase II dose of Onapristone (ZK299) has been determined in female patients with Pgr positive endometrial, ovarian, and breast cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4512).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1886,
                "therapyName": "Onapristone",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3583,
                    "pubMedId": null,
                    "title": "Onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers: PK results from part 1 of a randomized, parallel-dose phase 1 study",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/4512.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14542,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-7) that supported FDA approval, Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (Femara (letrozole) or Arimidex (anastrozole)) resulted in significantly improved median progression-free survival (23.8 vs 13.0 months, HR=0.55, p<0.0001) compared to placebo in premenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 29804902; NCT02278120).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 7166,
                "therapyName": "Anastrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11737,
                    "pubMedId": 29804902,
                    "title": "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29804902"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3029,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the recommended phase II dose of Onapristone (ZK299) has been determined in female patients with Pgr positive endometrial, ovarian, and breast cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4512).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1886,
                "therapyName": "Onapristone",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3583,
                    "pubMedId": null,
                    "title": "Onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers: PK results from part 1 of a randomized, parallel-dose phase 1 study",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/4512.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11836,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MONARCH 1) that supported FDA approval, Verzenio (abemaciclib) treatment resulted in an objective response rate of 19.7% (26/132), a clinical benefit rate of 42.4% (56/132), median progression-free survival of 6.0 months, and median overall survival of 17.7 months in patients with refractory hormone receptor positive, Erbb2 (Her2) negative metastatic breast cancer (PMID: 28533223; NCT02102490).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9866,
                    "pubMedId": 28533223,
                    "title": "MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28533223"
                },
                {
                    "id": 15550,
                    "pubMedId": null,
                    "title": "Verzenio (abemaciclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18082,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, combination of Afinitor (everolimus) and Faslodex (fulvestrant) was associated with improved survival (p<0.05) in patients with hormone receptor-positive metastatic breast cancer (PMID: 31088410).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15992,
                    "pubMedId": 31088410,
                    "title": "Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31088410"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4268,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Cixutumumab treatment had no beneficial effects on progression-free survival and overall survival in patients with hormone receptor positive (Esr1 and/or Pgr positive) breast adenocarcinoma (PMID: 26324738).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 701,
                "therapyName": "Cixutumumab",
                "synonyms": null
            },
            "indication": {
                "id": 3458,
                "name": "breast adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4473,
                    "pubMedId": 26324738,
                    "title": "Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26324738"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14538,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (MONALEESA-3) trial that supported FDA approval, Faslodex (fulvestrant) in combination with Kisqali (ribociclib) resulted in significantly improved median progression-free survival (20.5 vs 12.8 months, HR=0.593, p<0.001) compared to Faslodex (fulvestrant) plus placebo in postmenopausal women with hormone receptor-positive, Erbb2 (Her2)-negative, advanced breast cancer (PMID: 29860922; NCT02422615).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 2316,
                "therapyName": "Fulvestrant + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11736,
                    "pubMedId": 29860922,
                    "title": "Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29860922"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16913,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (BOLERO-2) that supported FDA approval, the combination of Afinitor (everolimus) and Aromasin (exemestane) resulted in an improved median progression-free survival (7.8 vs 3.2 months) compared to Aromasin (exemestane) and placebo in patients with ERBB2 (HER2)-negative, hormone receptor-positive breast cancer whose disease recurred or progressed during or after nonsteroidal aromatase inhibitor therapy (PMID: 24158787; NCT00863655).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1966,
                "therapyName": "Everolimus + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10766,
                    "pubMedId": 24158787,
                    "title": "Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24158787"
                },
                {
                    "id": 15547,
                    "pubMedId": null,
                    "title": "Afinitor (everolimus) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1587,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Onapristone (ZK299) demonstrated safety and was well-tolerated in female patients with Pgr positive endometrial, ovarian, and breast cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4512).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1886,
                "therapyName": "Onapristone",
                "synonyms": null
            },
            "indication": {
                "id": 60077,
                "name": "progesterone-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3583,
                    "pubMedId": null,
                    "title": "Onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers: PK results from part 1 of a randomized, parallel-dose phase 1 study",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/4512.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12093,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONARCH 2) that supported FDA approval, the combination treatment of Verzenio (abemaciclib) and Faslodex (fulvestrant) resulted in a greater median progression-free survival compared to Faslodex (fulvestrant) plus placebo (16.4 mo vs 9.3 mo, HR=0.553, p<0.0001) and improved objective response rate (48.1% vs 21.3 %) in hormone receptor-positive, ERBB2 (HER2) receptor-negative breast cancer patients (PMID: 28580882; NCT02107703).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 5859,
                "therapyName": "Abemaciclib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9173,
                    "pubMedId": 28580882,
                    "title": "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28580882"
                },
                {
                    "id": 15550,
                    "pubMedId": null,
                    "title": "Verzenio (abemaciclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4578,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, combination treatment of Buparlisib (BKM120) and Falsodex (fulvestrant) resulted in improved progression-free survival (6.9 months) in hormone receptor-positive breast cancer patients compared to Falsodex (fulvestrant) treatment alone (5.0 months) (PMID: 26681740).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 1546,
                "therapyName": "Buparlisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60077,
                "name": "progesterone-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4620,
                    "pubMedId": 26681740,
                    "title": "PI3K Inhibitor Improves PFS in BELLE-2 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26681740"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13886,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ATAC) that supported FDA approval, Arimidex (anastrozole) treatment resulted in prolonged disease-free survival (HR=0.87, p=0.01) and time-to-recurrence (HR=0.79, p=0.0005), and decreased distant metastases (HR=0.86, p=0.04) and contralateral breast cancers (42% reduction, p=0.01) compared to Nolvadex (tamoxifen) in patients with hormone receptor-positive breast cancer (PMID: 15639680).",
            "molecularProfile": {
                "id": 1856,
                "profileName": "PGR positive"
            },
            "therapy": {
                "id": 633,
                "therapyName": "Anastrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60077,
                "name": "progesterone-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11329,
                    "pubMedId": 15639680,
                    "title": "Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15639680"
                },
                {
                    "id": 15551,
                    "pubMedId": null,
                    "title": "Arimidex (anastrozole) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020541"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2388,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Telapristone inhibited cell proliferation and decreased both PR and ER signaling a PR and ER positive human breast carcinoma cell line (PMID: 21119048).",
            "molecularProfile": {
                "id": 7400,
                "profileName": "ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 2820,
                "therapyName": "Telapristone",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3019,
                    "pubMedId": 21119048,
                    "title": "CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21119048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4269,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Cixutumumab treatment had no beneficial effects on progression-free survival and overall survival in patients with hormone receptor positive (Esr1 and/or Pgr positive) breast adenocarcinoma (PMID: 26324738).",
            "molecularProfile": {
                "id": 7400,
                "profileName": "ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 701,
                "therapyName": "Cixutumumab",
                "synonyms": null
            },
            "indication": {
                "id": 3458,
                "name": "breast adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4473,
                    "pubMedId": 26324738,
                    "title": "Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26324738"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2387,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lonaprisan inhibited cell cycle progression of PGR and ESR1 positive human breast carcinoma cells in culture (PMID: 20043998).",
            "molecularProfile": {
                "id": 7400,
                "profileName": "ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 2818,
                "therapyName": "Lonaprisan",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3020,
                    "pubMedId": 20043998,
                    "title": "In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20043998"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13040,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Nolvadex (tamoxifen), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6714,
                "therapyName": "Carboplatin + Docetaxel + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17070,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Arimidex (anastrozole) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8401,
                "therapyName": "Anastrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12958,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Aromasin (exemestane), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6708,
                "therapyName": "Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17084,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Aromasin (exemestane), Tykerb (lapatinib), and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8409,
                "therapyName": "Exemestane + Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17086,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Faslodex (fulvestrant) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8410,
                "therapyName": "Fulvestrant + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17079,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Arimidex (anastrozole), Tykerb (lapatinib), and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8407,
                "therapyName": "Anastrozole + Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13046,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Aromasin (exemestane), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6721,
                "therapyName": "Carboplatin + Docetaxel + Exemestane + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13041,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6715,
                "therapyName": "Anastrozole + Carboplatin + Docetaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17057,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Arimidex (anastrozole), is iincluded in the guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6720,
                "therapyName": "Anastrozole + Carboplatin + Docetaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13036,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Nolvadex (tamoxifen), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6710,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17073,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Aromasin (exemestane) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8404,
                "therapyName": "Exemestane + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17075,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Femara (letrozole) and Tykerb (lapatinib) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 1497,
                "therapyName": "Lapatinib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17092,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Nolvadex (tamoxifen) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8411,
                "therapyName": "Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13038,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6712,
                "therapyName": "Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13037,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Femara (letrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6711,
                "therapyName": "Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12956,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Femara (letrozole) is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6707,
                "therapyName": "Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13044,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Nolvadex (tamoxifen), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6718,
                "therapyName": "Carboplatin + Docetaxel + Pertuzumab + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12942,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Nolvadex (tamoxifen) is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6704,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13039,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Aromasin (exemestane), is indicated in guidelines for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6713,
                "therapyName": "Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12955,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6706,
                "therapyName": "Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17074,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Arimidex (anastrozole) and Tykerb (lapatinib) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8405,
                "therapyName": "Anastrozole + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17078,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Aromasin (exemestane) and Tykerb (lapatinib) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8406,
                "therapyName": "Exemestane + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13042,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Femara (letrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6716,
                "therapyName": "Carboplatin + Docetaxel + Letrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13043,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Aromasin (exemestane), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6717,
                "therapyName": "Carboplatin + Docetaxel + Exemestane + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17083,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Femara (letrozole), Tykerb (lapatinib), and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8408,
                "therapyName": "Lapatinib + Letrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13045,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Femara (letrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6719,
                "therapyName": "Carboplatin + Docetaxel + Letrozole + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17072,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Femara (letrozole) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8403,
                "therapyName": "Letrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7139,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with LY3039478 resulted in partial response in one patient with ER-positive, PR-positive, ERBB2 (HER2)-negative breast cancer (J Clin Oncol 33, 2015 (suppl; abstr 2533)).",
            "molecularProfile": {
                "id": 24496,
                "profileName": "ERBB2 neg ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5879,
                    "pubMedId": null,
                    "title": "First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer",
                    "url": "http://meetinglibrary.asco.org/content/144588-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7479,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, Xgeva (denosumab) inhibited cell proliferation in 3D-organoid culture of PGR-positive human breast tissues harboring BRCA1 mutations, provided a potential strategy to prevent breast cancer in this population (PMID: 27322743).",
            "molecularProfile": {
                "id": 25527,
                "profileName": "BRCA1 mut PGR pos"
            },
            "therapy": {
                "id": 1198,
                "therapyName": "Denosumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6366,
                    "pubMedId": 27322743,
                    "title": "RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27322743"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11224,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Abemaciclib (LY2835219) and Faslodex (fulvestrant) combination therapy resulted in improved median progression free survival (16.4 vs 9.3 months) and overall response rate (48.1% vs 21.3%) compared to placebo in patients with treatment refractory hormone receptor positive, Erbb2 (Her2) negative breast cancer (PMID: 28580882).",
            "molecularProfile": {
                "id": 27930,
                "profileName": "ERBB2 neg PGR pos"
            },
            "therapy": {
                "id": 5859,
                "therapyName": "Abemaciclib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60077,
                "name": "progesterone-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9173,
                    "pubMedId": 28580882,
                    "title": "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28580882"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12842,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with the combination of Tykerb (lapatinib) and Femara (letrozole) resulted in an improved median progression-free survival of 8.2 months compared to 3.0 months with Femara (letrozole) plus placebo in patients with hormone receptor-positive metastatic breast cancer that is also ERBB2 (HER2)-positive (defined as FISH positive, IHC 3+, or FISH pos and IHC 2+) (PMID: 19786658; NCT00073528).",
            "molecularProfile": {
                "id": 28937,
                "profileName": "ERBB2 over exp PGR pos"
            },
            "therapy": {
                "id": 1497,
                "therapyName": "Lapatinib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60077,
                "name": "progesterone-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2500,
                    "pubMedId": 19786658,
                    "title": "Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19786658"
                },
                {
                    "id": 15539,
                    "pubMedId": null,
                    "title": "Tykerb (lapatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17719,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NEO-ORB), Piqray (Alpelisib) and Femara (letrozole) combination treatment in the neoadjuvant setteing did not improve objective response rate (26/40, 43.3% vs 30/67, 44.8%) or pathologic complete response rate (1/60, 1.7% vs 2/67, 3.0%) compared to Femara (letrozole) plus placebo in patients with hormone receptor-positive, ERBB2 (HER2)-negative, PIK3CA mutant breast cancer (PMID: 30723140; NCT01923168).",
            "molecularProfile": {
                "id": 32749,
                "profileName": "PGR pos PIK3CA mut"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15751,
                    "pubMedId": 30723140,
                    "title": "A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30723140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4580,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, combination treatment of Buparlisib (BKM120) and Falsodex (fulvestrant) resulted in improved progression-free survival (7.0 months) in hormone receptor-positive breast cancer patients harboring PIK3CA mutations compared to Falsodex (fulvestrant) treatment alone (3.2 months) (PMID: 26681740).",
            "molecularProfile": {
                "id": 32749,
                "profileName": "PGR pos PIK3CA mut"
            },
            "therapy": {
                "id": 1546,
                "therapyName": "Buparlisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60077,
                "name": "progesterone-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4620,
                    "pubMedId": 26681740,
                    "title": "PI3K Inhibitor Improves PFS in BELLE-2 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26681740"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19571,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 32749,
                "profileName": "PGR pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19572,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Faslodex (fulvestrant) and Piqray (alpelisib) is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring a PIK3CA mutation (NCCN.org).",
            "molecularProfile": {
                "id": 32749,
                "profileName": "PGR pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17724,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NEO-ORB), Piqray (Alpelisib) and Femara (letrozole) combination treatment in the neoadjuvant setteing did not improve objective response rate (45/71, 63.4% vs 36/59, 61.0%) or pathologic complete response rate (2/71, 2.8% vs 1/59, 1.7%) compared to Femara (letrozole) plus placebo in patients with hormone receptor-positive, ERBB2 (HER2)-negative, PIK3CA wild-type breast cancer (PMID: 30723140; NCT01923168).",
            "molecularProfile": {
                "id": 32754,
                "profileName": "PGR pos PIK3CA wild-type"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15751,
                    "pubMedId": 30723140,
                    "title": "A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30723140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18277,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCND1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.471 and 0.594 (p=0.503) in CCND1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33095,
                "profileName": "CCND1 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18279,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDK4 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.509 and 0.562 (p=0.627) in CDK4 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33097,
                "profileName": "CDK4 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18281,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDK6 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.605 and 0.483 (p=0.515) in CDK6 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33099,
                "profileName": "CDK6 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18283,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), RB1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.425 and 0.672 (p=0.123) in RB1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33101,
                "profileName": "PGR pos RB1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18290,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCNE1 expression level negatively correlates with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.320 and 0.851 (p=0.00238) in CCNE1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33103,
                "profileName": "CCNE1 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18285,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDKN2A expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.504 and 0.555 (p=0.730) in CDKN2A low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33111,
                "profileName": "CDKN2A pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18287,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCNE2 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.513 and 0.560 (p=0.834) in CCNE2 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33116,
                "profileName": "CCNE2 pos PGR pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18810,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Faslodex (fulvestrant) and Piqray (alpelisib) is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring a PIK3CA mutation (NCCN.org).",
            "molecularProfile": {
                "id": 33604,
                "profileName": "ESR1 pos PGR pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19573,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA C420R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34229,
                "profileName": "PGR pos PIK3CA C420R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19574,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E542K (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34230,
                "profileName": "PGR pos PIK3CA E542K"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19575,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545A (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34231,
                "profileName": "PGR pos PIK3CA E545A"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19576,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545D (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34232,
                "profileName": "PGR pos PIK3CA E545D"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19577,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545G (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34233,
                "profileName": "PGR pos PIK3CA E545G"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19578,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545K (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34234,
                "profileName": "PGR pos PIK3CA E545K"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19579,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047L (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34235,
                "profileName": "PGR pos PIK3CA H1047L"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19580,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34236,
                "profileName": "PGR pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19581,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047Y (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34237,
                "profileName": "PGR pos PIK3CA H1047Y"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19582,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA Q546E (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34238,
                "profileName": "PGR pos PIK3CA Q546E"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19583,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA Q546R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34239,
                "profileName": "PGR pos PIK3CA Q546R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1856,
            "profileName": "PGR positive",
            "profileTreatmentApproaches": [
                {
                    "id": 5525,
                    "name": "Hormone - Anti-progestins",
                    "profileName": "PGR positive"
                }
            ]
        },
        {
            "id": 7400,
            "profileName": "ESR1 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17882,
            "profileName": "ERBB2 pos ESR1 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24496,
            "profileName": "ERBB2 neg ESR1 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25527,
            "profileName": "BRCA1 mut PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27930,
            "profileName": "ERBB2 neg PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28937,
            "profileName": "ERBB2 over exp PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31167,
            "profileName": "ESR1 neg PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31229,
            "profileName": "ERBB2 neg PGR pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31230,
            "profileName": "ERBB2 neg ESR1 pos PGR pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31232,
            "profileName": "ERBB2 neg PGR pos PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31233,
            "profileName": "ERBB2 neg ESR1 pos PGR pos PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31236,
            "profileName": "ERBB2 neg PGR pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31237,
            "profileName": "ERBB2 neg ESR1 pos PGR pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32749,
            "profileName": "PGR pos PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32754,
            "profileName": "PGR pos PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33095,
            "profileName": "CCND1 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33097,
            "profileName": "CDK4 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33099,
            "profileName": "CDK6 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33101,
            "profileName": "PGR pos RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33103,
            "profileName": "CCNE1 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33111,
            "profileName": "CDKN2A pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33116,
            "profileName": "CCNE2 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33604,
            "profileName": "ESR1 pos PGR pos PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34229,
            "profileName": "PGR pos PIK3CA C420R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34230,
            "profileName": "PGR pos PIK3CA E542K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34231,
            "profileName": "PGR pos PIK3CA E545A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34232,
            "profileName": "PGR pos PIK3CA E545D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34233,
            "profileName": "PGR pos PIK3CA E545G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34234,
            "profileName": "PGR pos PIK3CA E545K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34235,
            "profileName": "PGR pos PIK3CA H1047L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34236,
            "profileName": "PGR pos PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34237,
            "profileName": "PGR pos PIK3CA H1047Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34238,
            "profileName": "PGR pos PIK3CA Q546E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34239,
            "profileName": "PGR pos PIK3CA Q546R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}